CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is set to showcase critical new findings on resmetirom, its liver-targeted thyroid hormone receptor (THR)-β agonist, at the European Association for the Study of the Liver (EASL) Congress in Amsterdam, from May 7 to May 10, 2025. Anchoring the presentations is a late-breaking oral session on two-year data from the Phase 3 MAESTRO-NAFLD-1 trial, which focuses on patients with compensated metabolic-associated steatohepatitis (MASH) cirrhosis.
“Patients with compensated MASH cirrhosis who develop clinically significant portal hypertension are at greatly elevated risk of experiencing life-threatening complications of late-stage liver disease,” said Bill Sibold, Madrigal’s Chief Executive Officer. “The late-breaking data we will be presenting at EASL suggest that resmetirom may help halt or reverse disease progression in patients with compensated MASH cirrhosis.”
The presentation, scheduled for May 10, will outline improvements in liver stiffness, fibrosis biomarkers, and portal hypertension risk observed in 122 patients after two years of resmetirom treatment. Highlighting a broader goal, Mr. Sibold emphasized resmetirom’s potential as “the foundational therapy across F2 to F4c MASH.”
Currently, resmetirom is approved in the U.S. for the treatment of noncirrhotic MASH in adults with moderate to advanced liver fibrosis (F2 to F3) when used alongside diet and exercise. Madrigal awaits a decision from the European Medicines Agency (EMA) on its marketing authorization application (MAA) and plans to launch resmetirom in select European countries, starting with Germany, in late 2025 upon approval.
Neil Archer, Madrigal’s Executive Vice President and Head of International, noted that the EASL Congress is an opportune moment to engage with stakeholders across Europe. “This EASL Congress comes at an ideal time for our growing team in Europe,” he said.
Madrigal will also present an array of posters at the event, including insights into diagnostic methods, clinical outcomes, and the epidemiology of MASH. These data, complemented by an investor webcast on May 13, underscore Madrigal’s ongoing commitment to advancing the treatment landscape for liver diseases.
Resmetirom is positioned as a potential game-changer for the millions of patients worldwide facing severe complications from MASH, strengthening Madrigal’s leadership in global liver health innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.